, Dans notre étude, entre C1 et C2, le taux d'ACE a augmenté chez 21/53 (39,6 %) patients, parmi eux 17/21 (81 %) n'ont pas présenté de progression radiologique à M3. Entre C1 et C3, le taux d'ACE a augmenté chez 17/50 (34 %) patients, parmi eux 15/17 (88,2 %) n'ont pas présenté de progression radiologique à M3. Ces données confirment les observations menées par Sorbye et coll. qui avaient décrit un « flare up, p.0

, CONCLUSION Nos résultats issus de l'analyse préliminaire de l'étude prospective COCA-MACS confirment la valeur pronostique des taux initiaux d'ADN total et d'ADN tumoral circulant dans le cancer colorectal métastatique

, Nous montrons une association significative entre la variation précoce de l'ADN

, 2 cures de chimiothérapie ainsi que sa cinétique calculée entre l'inclusion et la 2 ème cure de chimiothérapie et la survie sans progression. Nos résultats offrent la perspective d'un monitoring précoce de l'ADN tumoral circulant, permettant de préciser le pronostic à long terme et d'adapter de manière précoce la stratégie thérapeutique en première ligne de chimiothérapie

F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: A Cancer Journal for Clinicians, vol.68, issue.6, pp.394-424, 2018.

N. Howlader, A. M. Noone, M. Krapcho, D. Miller, A. Brest et al.,

A. Mariotto, D. R. Lewis, H. S. Chen, E. J. Feuer, and K. A. Cronin, SEER Cancer Statistics Review, 1975.

H. Brenner, M. Kloor, and C. P. Pox, Colorectal cancer. Lancet, vol.383, issue.9927, pp.1490-502, 2014.

D. P. Taylor, R. W. Burt, M. S. Williams, P. J. Haug, and L. A. Cannon-albright, Population-based family history-specific risks for colorectal cancer: a constellation approach, Gastroenterology, vol.138, issue.3, pp.877-85, 2010.

A. K. Win, M. A. Jenkins, J. G. Dowty, A. C. Antoniou, A. Lee et al., Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer, Cancer Epidemiol Biomarkers Prev, vol.26, issue.3, pp.404-416, 2017.

J. G. Dowty, A. K. Win, D. D. Buchanan, N. M. Lindor, F. A. Macrae et al.,

, Cancer risks for MLH1 and MSH2 mutation carriers, Hum Mutat, vol.34, issue.3, pp.490-497, 2013.

B. Buecher, Colorectal adenomatous polyposis syndromes: Genetic determinism, clinical presentation and recommendations for care, Bull Cancer, vol.103, issue.2, pp.199-209, 2016.

J. Rosenbluh, X. Wang, and W. C. Hahn, Genomic insights into WNT/?-catenin signaling

, Trends Pharmacol Sci, vol.35, issue.2, pp.103-112, 2014.

H. Aihara, N. Kumar, and C. C. Thompson, Diagnosis, surveillance, and treatment strategies for familial adenomatous polyposis: rationale and update, Eur J Gastroenterol Hepatol, 2014.

M. Buyse, P. Thirion, R. W. Carlson, T. Burzykowski, G. Molenberghs et al., Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer, Lancet, vol.356, issue.9227, pp.373-381, 2000.

C. Giessen, R. P. Laubender, L. Fischer-von-weikersthal, A. Schalhorn, and D. P. Modest,

S. Stintzing, Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial, Cancer Sci, vol.104, issue.6, pp.718-742, 2013.

C. Cremolini, F. Loupakis, C. Antoniotti, S. Lonardi, G. Masi et al., Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest, Ann Oncol, vol.26, issue.6, pp.1188-94, 2015.

M. Karoui, C. Penna, M. Amin-hashem, E. Mitry, S. Benoist et al., Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases

, Ann Surg, vol.243, issue.1, pp.1-7, 2006.

J. M. Phelip, L. Benhaim, O. Bouché, N. Christou, G. Desolneux et al.,

P. Michel, C. Penna, B. Rousseaux, D. Tougeron, and C. Tournigand, «Cancer colorectal métastatique». Thésaurus National de Cancérologie Digestive, 2019.

E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), Eur J Cancer, vol.45, issue.2, pp.228-275, 2009.

M. Bellomi, D. Piano, F. Ancona, E. Lodigiani, A. F. Curigliano et al.,

, Evaluation of inter-observer variability according to RECIST 1.1 and its influence on response classification in CT measurement of liver metastases, Eur J Radiol, vol.95, pp.96-101, 2017.

Y. S. Chun, J. Vauthey, P. Boonsirikamchai, D. M. Maru, S. Kopetz et al.,

, Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases, JAMA, vol.302, issue.21, pp.2338-2382, 2009.

M. R. Sharma, M. L. Maitland, and M. J. Ratain, RECIST: No Longer the Sharpest Tool in the Oncology Clinical Trials Toolbox-Point, Cancer Res, vol.72, issue.20, pp.5145-5154, 2012.

J. C. Yao, M. H. Shah, T. Ito, C. L. Bohas, E. M. Wolin et al., Everolimus for advanced pancreatic neuroendocrine tumors, N Engl J Med, vol.364, issue.6, pp.514-537, 2011.

A. Grothey, E. V. Cutsem, A. Sobrero, S. Siena, A. Falcone et al., Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial, Lancet, vol.381, issue.9863, pp.303-315, 2013.

J. Edeline, E. Boucher, Y. Rolland, E. Vauléon, M. Pracht et al., Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma, Cancer, vol.118, issue.1, pp.147-56, 2012.

M. C. Tan, D. C. Linehan, W. G. Hawkins, B. A. Siegel, and S. M. Strasberg, Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response, J Gastrointest Surg, vol.11, issue.9, pp.1112-1121, 2007.

. Geus-oei-l-f-de, D. Vriens, H. Laarhoven, . Van, . Graaf-wta-van-der et al.,

, Monitoring and Predicting Response to Therapy with 18F-FDG PET in Colorectal Cancer: A Systematic Review, J Nucl Med, vol.50, issue.1, pp.43-54, 2009.

R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge, From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors, J Nucl Med, vol.50, issue.1, pp.122-150, 2009.

P. Byström, A. Berglund, U. Garske, H. Jacobsson, A. Sundin et al., Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-Dglucose positron emission tomography in patients with advanced colorectal cancer, Ann Oncol, vol.20, issue.6, pp.1057-61, 2009.

F. Liu, Y. Wang, J. , and Y. , Early prediction by 18F-FDG PET/CT for progression-free survival and overall survival in patients with metastatic colorectal cancer receiving third-line cetuximab-based therapy, Clin Nucl Med, vol.40, issue.3, pp.200-205, 2015.

M. Findlay, H. Young, D. Cunningham, A. Iveson, B. Cronin et al., Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil, J Clin Oncol, vol.14, issue.3, pp.700-708, 1996.

H. Bender, N. Bangard, N. Metten, M. Bangard, J. Mezger et al., Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer, Hybridoma, vol.18, issue.1, pp.87-91, 1999.

L. F. De-geus-oei, H. Van-laarhoven, E. P. Visser, R. Hermsen, B. A. Van-hoorn et al.,

. Yjl, Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer, Ann Oncol, vol.19, issue.2, pp.348-52, 2008.

A. Hendlisz, V. Golfinopoulos, C. Garcia, A. Covas, P. Emonts et al., Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy, Ann Oncol, vol.23, issue.7, pp.1687-93, 2012.

Y. S. Hong, H. O. Kim, K. Kim, J. Lee, H. J. Kim et al., 3?-Deoxy-3?-18F

, Fluorothymidine PET for the Early Prediction of Response to Leucovorin, 5-Fluorouracil, and Oxaliplatin Therapy in Patients with Metastatic Colorectal Cancer, J Nucl Med, vol.54, issue.8, pp.1209-1225, 2013.

E. Woff, A. Hendlisz, C. Garcia, A. Deleporte, T. Delaunoit et al., Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer, Eur J Nucl Med Mol Imaging, vol.43, issue.10, pp.1792-801, 2016.

M. B. Mogensen, A. Loft, M. Aznar, T. Axelsen, B. Vainer et al., FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study, EJNMMI Res, vol.7, issue.1, p.56, 2017.

M. D. Pickles, P. Gibbs, M. Lowry, and L. W. Turnbull, Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer, Magn Reson Imaging, vol.24, issue.7, pp.843-850, 2006.

V. N. Harry, S. I. Semple, D. E. Parkin, and F. J. Gilbert, Use of new imaging techniques to predict tumour response to therapy, Lancet Oncology, vol.11, issue.1, pp.92-102, 2010.

D. Koh, E. Scurr, D. Collins, B. Kanber, A. Norman et al., Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients

, AJR Am J Roentgenol, vol.188, issue.4, pp.1001-1009, 2007.

F. Donati, P. Boraschi, F. Pacciardi, R. Cervelli, M. Castagna et al., 3T diffusionweighted MRI in the response assessment of colorectal liver metastases after chemotherapy: Correlation between ADC value and histological tumour regression grading, Eur J Radiol, vol.91, pp.57-65, 2017.

W. M. Byun, S. O. Shin, Y. Chang, S. J. Lee, J. Finsterbusch et al., Diffusion-weighted MR imaging of metastatic disease of the spine: assessment of response to therapy, AJNR Am J Neuroradiol, vol.23, issue.6, pp.906-918, 2002.

C. Chen, C. Li, Y. Kuo, T. Jaw, D. Wu et al., Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants--initial experience, Radiology, vol.239, issue.2, pp.448-56, 2006.

H. Xie, T. Sun, M. Chen, H. Wang, X. Zhou et al., Effectiveness of the Apparent Diffusion Coefficient for Predicting the Response to Chemoradiation Therapy in Locally Advanced Rectal Cancer, Medicine, vol.94, issue.6, p.517, 2015.

R. Sugita, K. Ito, N. Fujita, and S. Takahashi, Diffusion-weighted MRI in abdominal oncology: Clinical applications, World J Gastroenterol, vol.16, issue.7, pp.832-838, 2010.

P. Gold and S. O. Freedman, Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques, J Exp Med, vol.121, pp.439-62, 1965.

J. Hashino, Y. Fukuda, S. Oikawa, H. Nakazato, and T. Nakanishi, Metastatic potential of human colorectal carcinoma SW1222 cells transfected with cDNA encoding carcinoembryonic antigen, Clin Exp Metastasis, vol.12, issue.4, pp.324-332, 1994.

M. J. Duffy, Carcinoembryonic Antigen as a Marker for Colorectal Cancer: Is It Clinically Useful?, Clin Chem, vol.47, issue.4, pp.624-654, 2001.

H. J. Wanebo, B. Rao, C. M. Pinsky, R. G. Hoffman, M. Stearns et al.,

, Preoperative Carcinoembryonic Antigen Level as a Prognostic Indicator in Colorectal Cancer

, N Engl J Med, vol.299, issue.9, pp.448-51, 1978.

R. C. Bast, P. Ravdin, D. F. Hayes, S. Bates, H. Fritsche et al., Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the, J Clin Oncol, vol.19, issue.6, pp.1865-78, 2000.

I. Iwanicki-caron, D. Fiore, F. Roque, I. Astruc, E. Stetiu et al., Usefulness of the Serum Carcinoembryonic Antigen Kinetic for Chemotherapy Monitoring in Patients With Unresectable Metastasis of Colorectal Cancer, J Clin Oncol, vol.26, issue.22, pp.3681-3687, 2008.

D. Sefrioui, N. Vasseur, E. Toure, F. Blanchard, J. Delacour et al., Prospective analysis of CEA, circulating DNA (cDNA) and circulating tumor cells (CTC) kinetics in patients (pts) treated for a metastatic colorectal cancer (mCRC), Ann Oncol, vol.27, issue.6, p.71, 2016.

H. Sørbye and O. Dahl, Carcinoembryonic Antigen Surge in Metastatic Colorectal Cancer Patients Responding to Oxaliplatin Combination Chemotherapy: Implications for Tumor Marker Monitoring and Guidelines, J Clin Oncol, vol.21, issue.23, pp.4466-4473, 2003.

K. Pantel, A. , and C. , Liquid biopsy and minimal residual disease -latest advances and implications for cure, Nat Rev Clin Oncol, vol.16, issue.7, pp.409-433, 2019.

S. J. Cohen, R. K. Alpaugh, S. Gross, S. M. O'hara, D. A. Smirnov et al.,

, Isolation and Characterization of Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer, Clin Colorectal Cancer, vol.6, issue.2, pp.125-157, 2006.

S. J. Cohen, C. Punt, N. Iannotti, B. H. Saidman, K. D. Sabbath et al.,

, Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer

, Ann Oncol, vol.20, issue.7, pp.1223-1232, 2009.

J. Tol, M. Koopman, M. C. Miller, A. Tibbe, A. Cats et al., Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents, Ann Oncol, vol.21, issue.5, pp.1006-1018, 2010.

S. J. Cohen, C. Punt, N. Iannotti, B. H. Saidman, K. D. Sabbath et al.,

, Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer, J Clin Oncol, vol.26, pp.3213-3234, 2008.

J. Barbazán, L. Muinelo-romay, M. Vieito, S. Candamio, A. Díaz-lópez et al., A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer, Int J Cancer, vol.135, issue.11, pp.2633-2676, 2014.

L. Silva-vs-e,-chinen, E. A. Abdallah, A. Damascena, J. Paludo, and R. Chojniak, Early detection of poor outcome in patients with metastatic colorectal cancer: tumor kinetics evaluated by circulating tumor cells, Onco Targets Ther, vol.13, issue.9, pp.7503-7516, 2016.

R. B. Corcoran and B. A. Chabner, Application of Cell-free DNA Analysis to Cancer Treatment, N Engl J Med, vol.379, issue.18, pp.1754-65, 2018.

S. A. Leon, B. Shapiro, D. M. Sklaroff, and M. J. Yaros, Free DNA in the Serum of Cancer Patients and the Effect of Therapy, Cancer Res, vol.37, issue.3, pp.646-50, 1977.

E. Crowley, D. Nicolantonio, F. Loupakis, F. Bardelli, and A. , Liquid biopsy: monitoring cancer-genetics in the blood, Nat Rev Clin Oncol, vol.10, issue.8, pp.472-84, 2013.

G. Siravegna, S. Marsoni, S. Siena, and A. Bardelli, Integrating liquid biopsies into the management of cancer, Nat Rev Clin Oncol, vol.14, issue.9, pp.531-579, 2017.

F. Diehl, M. Li, D. Dressman, Y. He, D. Shen et al., Detection and quantification of mutations in the plasma of patients with colorectal tumors, Proc Natl Acad Sci, 2005.

G. Sozzi, D. Conte, L. Mariani, L. Vullo, S. et al., Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients, Cancer Res, vol.61, issue.12, pp.4675-4683, 2001.

C. Bettegowda, M. Sausen, R. J. Leary, I. Kinde, Y. Wang et al., Detection of Circulating Tumor DNA in Early-and Late-Stage Human Malignancies, Sci Transl Med, 2014.

S. El-messaoudi, F. Rolet, F. Mouliere, and A. R. Thierry, Circulating cell free DNA: Preanalytical considerations, Clin Chim Acta, vol.424, pp.222-252, 2013.

L. A. Diaz and A. Bardelli, Liquid Biopsies: Genotyping Circulating Tumor DNA, J Clin Oncol, vol.32, issue.6, pp.579-86, 2014.

G. Perkins, H. Lu, F. Garlan, and V. Taly, Droplet-Based Digital PCR: Application in Cancer Research. Makowski GS, Adv Clin Chem, vol.79, pp.43-91, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02299530

A. D. Cox, S. W. Fesik, A. C. Kimmelman, J. Luo, and C. J. Der, Drugging the undruggable RAS: Mission possible?, Nat Rev Drug Discov, vol.13, issue.11, pp.828-51, 2014.

A. Thiel and A. Ristimäki, Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF, Front Oncol, vol.3, p.281, 2013.

K. Spindler, A. Appelt, N. Pallisgaard, R. Andersen, I. Brandslund et al., Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer, Int J Cancer, vol.135, issue.12, pp.2984-91, 2014.

A. Marchetti, J. F. Palma, L. Felicioni, T. Pas, R. Chiari et al., Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients, J Thorac Oncol, vol.10, issue.10, pp.1437-1480, 2015.

T. Mok, Y. Wu, J. S. Lee, C. Yu, V. Sriuranpong et al., Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

, Clin Cancer Res, vol.21, issue.14, pp.3196-203, 2015.

J. Y. Lee, X. Qing, W. Xiumin, B. Yali, C. S. Bak et al., Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02), Oncotarget, vol.7, issue.6, pp.6984-93, 2016.

S. B. Goldberg, A. Narayan, A. J. Kole, R. H. Decker, J. Teysir et al., Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA, Clin Cancer Res, vol.24, issue.8, pp.1872-80, 2018.

R. Raja, M. Kuziora, P. Z. Brohawn, B. W. Higgs, A. Gupta et al., Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab, Clin Cancer Res, vol.24, issue.24, pp.6212-6234, 2018.

Á. Taus, L. Camacho, P. Rocha, M. Hardy-werbin, L. Pijuan et al., Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma, Clin Lung Cancer, 2018.

E. Giroux-leprieur, G. Herbretau, C. Dumenil, J. C. , G. V. Labrune et al.,

, Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer, Oncoimmunology, vol.7, issue.5, p.1424675, 2018.

M. Schreuer, G. Meersseman, S. Van-den-herrewegen, Y. Jansen, I. Chevolet et al., Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors

, J Transl Med, vol.14, p.95, 2016.

L. Xi, T. Pham, E. C. Payabyab, R. M. Sherry, S. A. Rosenberg et al.,

, Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma, Clin Cancer Res, vol.22, issue.22, pp.5480-5486, 2016.

J. H. Lee, G. V. Long, S. Boyd, S. Lo, A. M. Menzies et al., Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma, Ann Oncol, vol.28, issue.5, pp.1130-1136, 2017.

G. Herbreteau, A. Vallée, A. Knol, S. Théoleyre, G. Quéreux et al., Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy, Oncotarget, vol.9, issue.38, pp.25265-76, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01810155

E. Capizzi, E. Gabusi, A. D. Grigioni, P. De-iaco, M. Rosati et al.,

, Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer, Diagn Mol Pathol, vol.17, issue.1, pp.34-42, 2008.

C. A. Parkinson, D. Gale, A. M. Piskorz, H. Biggs, C. Hodgkin et al., Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study

, PLoS Med, vol.13, issue.12, p.1002198, 2016.

S. Dawson, D. Tsui, M. Murtaza, H. Biggs, O. M. Rueda et al., Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer, N Engl J Med, vol.368, issue.13, pp.1199-209, 2013.

F. Clatot, A. Perdrix, A. L. Beaussire, L. Delacour, J. Calbrix et al., prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor, Oncotarget, vol.7, issue.46, pp.74448-59, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02353218

J. Tie, I. Kinde, Y. Wang, H. L. Wong, J. Roebert et al., Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer, Ann Oncol, vol.26, issue.8, pp.1715-1737, 2015.

F. Garlan, P. Laurent-puig, D. Sefrioui, N. Siauve, A. Didelot et al.,

, Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study), Clin Cancer Res, vol.23, issue.18, pp.5416-5441, 2017.

K. Spindler, N. Pallisgaard, R. F. Andersen, and A. Jakobsen, Changes in mutational status during third-line treatment for metastatic colorectal cancer-Results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma, Int J Cancer, vol.135, issue.9, 2014.

J. Vidal, L. Muinelo, A. Dalmases, F. Jones, D. Edelstein et al., Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients, Ann Oncol, vol.28, issue.6, pp.1325-1357, 2017.

F. Bidard, N. Kiavue, M. Ychou, L. Cabel, M. Stern et al., Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14, Trial. Cells, vol.8, issue.6, p.516, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02419551

A. White, L. Ironmonger, R. Steele, N. Ormiston-smith, C. Crawford et al., A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UK, BMC Cancer, vol.18, issue.1, p.906, 2018.

V. Heinemann, T. Decker, A. Kiani, U. Vehling-kaiser, and . Al-batran,

S. , FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial, Lancet Oncol, vol.15, issue.10, pp.1065-75, 2014.

T. Aparicio, F. Ghiringhelli, V. Boige, L. Malicot, K. Taieb et al.,

, Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in

, Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9, J Clin Oncol, 2018.

H. Piessevaux, M. Buyse, D. Roock, W. Prenen, H. Schlichting et al.,

, Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial), Ann Oncol, vol.20, issue.8, pp.1375-82, 2009.

C. Suzuki, L. Blomqvist, A. Sundin, H. Jacobsson, P. Byström et al., The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy, Ann Oncol, vol.23, issue.4, pp.948-54, 2012.

U. R. Mansmann, U. Sartorius, R. P. Laubender, C. A. Giessen, R. Esser et al.,

, Deepness of response: A quantitative analysis of its impact on post-progression survival time after first-line treatment in patients with mCRC, J Clin Oncol, vol.31, issue.4, pp.427-427, 2013.

A. Lemoine, S. Couraud, F. Fina, S. Lantuejoul, P. Lamy et al.,

, Recommandations du GFCO pour l'utilisation diagnostique des analyses génétiques somatiques sur l'ADN tumoral circulant, Innov Ther Oncol, vol.2, issue.5, pp.225-257, 2016.